Gilead’s AI Revolution: Solving Global Health | Next to Lead
Gilead Sciences moves at a pace rarely seen in pharma, delivering breakthrough COVID-19 antivirals and HIV preventatives in record time. Yet, in an industry facing a massive trust deficit, speed isn’t always enough. In this episode of Next to Lead, Johanna Mercier, Gilead’s Chief Commercial & Corporate Affairs Officer, joins Fortune’s Leadership Editor Ruth Umoh to discuss how the company is rewriting its narrative and balancing its patients with its shareholders. 00:00 Intro 01:05 Mercier’s role at Gilead 03:05 Work-life balance and managing energy 05:10 Mercier’s biology and business ba…
